East Tallinn Central Hospital
- Address
- Ravi Tn 18, Kesklinna Linnaosa, 10138 Tallin, Estonia
Gastroenterology and Immune-Mediated Disease Research
At East Tallinn Central Hospital, the Gastroenterology Centre is involved in studies across digestive system diseases and immune system diseases, with a focus on ulcerative colitis and rheumatoid arthritis. This work is aimed at evaluating new treatment options and understanding how well they control symptoms and support long-term disease management.
- Clinical research in ulcerative colitis is exploring whether new therapies can improve remission and disease control.
- Studies in rheumatoid arthritis are assessing treatment effectiveness, safety, and relief of joint inflammation.
- The site contributes to research on inflammatory conditions that affect both the gut and the immune system.
These trials help clarify how emerging therapies may improve day-to-day outcomes for people living with chronic inflammatory disease.
Musculoskeletal Health and Bone Disease Trials
The site also supports research in musculoskeletal diseases, especially post-menopausal osteoporosis and rheumatoid arthritis. The studies are designed to compare treatment effects, strengthen bone health, and assess whether new options can deliver similar benefits to established therapies.
- Post-menopausal osteoporosis research is focused on improving bone density and reducing bone loss.
- Rheumatoid arthritis studies evaluate symptom control and the ability to slow disease progression.
- These trials examine how well investigational treatments perform against current standards of care.
This area of research is important for patients living with chronic joint disease and age-related bone weakening.
Oncology Clinical Trials
Neoplasm research at the hospital includes studies in unresectable or metastatic melanoma. The main goal is to test whether newer cancer therapies can improve outcomes for patients with advanced disease while maintaining acceptable safety and tolerability.
- Melanoma trials are evaluating treatment effectiveness in advanced, hard-to-treat cancer.
- The research focuses on comparing new options with established immunotherapy approaches.
- These studies aim to expand treatment choices for patients with limited alternatives.
Work in this oncology area reflects the site’s involvement in both chronic disease and cancer research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 12 of 13 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in East Tallinn Central Hospital
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Morphic Therapeutic Inc. | Phase II | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.